Incyte vs United Therapeutics

Incyte (INCY), health care, and United Therapeutics (UTHR), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

United Therapeutics is worth $24.9B on the stock market and Incyte $24.3B: United Therapeutics is valued at 2% more. Incyte trades at 61.4 times earnings and United Therapeutics at 22.2; operating margins in their latest fiscal years were 29.5% and 46.9%. Over the past year Incyte's share price has moved +15.8% and United Therapeutics's +23.4%.

Key facts

Incyte market value
$24.3B
United Therapeutics market value
$24.9B
Incyte P/E
61.4
United Therapeutics P/E
22.2
Incyte revenue
$5.1BFY to 2025-12-31
United Therapeutics revenue
$3.2BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Incyte vs United Therapeutics: every measure side by side
Measure Incyte United Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$24.3Blower$24.9Bhigher
Revenue$5.1Bhigher$3.2Blower
Earnings$1.3Blower$1.3Bhigher
Employees2,844higher1,400lower
Total assets$7Blower$7.9Bhigher
Valuation
P/E61.4higher22.2lower
P/S4.7lower7.8higher
P/B4.3higher3.9lower
Dividend yield0.00%0.00%
Profitability
Operating margin29.5%lower46.9%higher
Balance sheet
Net assets$5.2Blower$7.1Bhigher
Total liabilities$1.8Bhigher$783.8Mlower
Total debt——
Cash on hand$3.1Bhigher$1.6Blower
Price change
Today-0.98%lower-0.64%higher
1 year+15.8%lower+23.4%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Incyte / United Therapeutics). Who owns INCY · Who owns UTHR

Further comparisons

Learn

Questions and answers

Which is bigger, Incyte or United Therapeutics?

By market value, United Therapeutics is the larger: $24.9B against $24.3B for Incyte. By revenue in its latest fiscal year, Incyte is the larger: $5.1B against $3.2B for United Therapeutics.

Which has the higher P/E ratio?

Incyte: 61.4, against 22.2 for United Therapeutics. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

United Therapeutics: 46.9%, against 29.5% for Incyte. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Incyte and United Therapeutics?

In their latest 13F filings, Jim Simons (1938–2024) holds both.

Cite this page

Funkfolio, “Incyte vs United Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/incy-vs-uthr

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.